Cell therapy developer Hopstem completed a $40m Eli Lilly-backed series B round while cybersecurity technology developer SlashNext secured $26m from investors including Telia and Ayala Group.

Funding Cayman Islands-registered cell therapy developer Hopstem closed almost $40m in series B funding yesterday from investors including Lilly Asia Ventures, a corporate venturing vehicle for pharmaceutical firm Eli Lilly. The round was led by an undisclosed venture capital firm and also featured YuanBio Venture Capital. It came after YuanBio led a $15.7m series A-plus-plus…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.